Navigation Links
Azur Pharma and Elan Corporation (NYSE: ELN) Sign Agreement to Develop a Once-Daily Clozapine
Date:11/10/2008

DUBLIN, November 10 /PRNewswire/ -- Azur Pharma Limited ("Azur") today announced that it has entered into an agreement to develop and commercialise once-daily formulations of clozapine using Elan Corporation plc's ("Elan")(NYSE:ELN) proprietary drug delivery technologies, including its NanoCrystal(r) technology.

Clozapine is currently marketed in immediate release presentations, including Azur's proprietary orally disintegrating tablet brand, FazaClo(r). Clozapine is indicated for the management of severely ill schizophrenic patients who fail to respond adequately to standard drug treatments for schizophrenia, and for reducing the risk of recurrent suicidal behaviour in patients with schizophrenia or schizoaffective disorders. Formulation development activities have been underway since 2007 under a preliminary agreement with Elan, and the companies have now elected to progress to a full development programme.

Seamus Mulligan, Chairman and Chief Executive of Azur, commented, "We are pleased to collaborate with Elan to apply their unique patented drug delivery technologies to this important drug. We have already made significant progress under our preliminary agreement. This represents a very significant commercial opportunity that will leverage Azur's existing infrastructure and knowledge of the clozapine market, and build on Azur's other FazaClo line extension programmes."

Under the terms of the agreement, Azur will be responsible for the clinical development programme, the regulatory approval process, and the commercialisation of the product in the US, with an option to expand its rights to countries outside the US. Elan will develop the formulation and manufacture the product. Elan will receive payments upon the achievement of development, clinical, and regulatory milestones, and manufacturing fees and royalties on sales of the product.

"This agreement continues to validate the robustness and flexibility of our technology platform. We look forward to progressing our work with Azur and assisting them in their efforts to bring a once-daily clozapine to the market," commented Shane Cooke, Executive Vice President, Chief Financial Officer and Head of Elan Drug Technologies.

About Azur Pharma Azur is a privately held pharmaceutical company dedicated to enhancing patients' lives by developing and marketing pharmaceutical products in specialist therapeutic areas. Azur's strategy is to identify, evaluate, selectively acquire and enhance the value of late stage development and approved pharmaceutical products. (Website: http://www.azurpharma.com)

NanoCrystal(r) Technology is a registered trademark of Elan Pharma International Limited, Ireland. For more information on Elan's drug delivery technologies including the NanoCrystal(r) Technology, please visit http://www.elan.com/EDT


'/>"/>
SOURCE Azur Pharma Limited
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Shengtai Pharmaceutical Schedules 2009 First Quarter Financial Results and Conference Call
2. Potentia Pharmaceuticals Drug Candidate for Age-Related Macular Degeneration Shows Positive Safety Profile in Phase I Clinical Trial
3. Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group
4. Idenix Pharmaceuticals to Present at Deutsche Banks 2008 Biotech Boston Confab
5. Pharmasset to Present at Two Upcoming Investor Conferences
6. Simcere Pharmaceutical Group to Participate in Morgan Stanley Seventh Annual Asia Pacific Summit 2008
7. Critical Pharmaceuticals Raise GBP650K
8. WellSpring Pharmaceutical Corp. Announces Hire of Wayne Miller as Vice President, Sales & Marketing, Consumer Brands
9. WuXi PharmaTech Signs New Collaboration Agreement With Pfizer
10. Onyx Pharmaceuticals Licenses Rights to Novel Targeted Oncology Agent From BTG International
11. Memory Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... VIC ... is joining the company’s board of directors. This addition continues to strengthen and ... said Calvin Goforth, CEO and Chairman. “He is a highly accomplished business executive with ...
(Date:7/20/2017)... July 20, 2017   KCNQ2 Cure Alliance ... evaluations company, today announced that they have completed ... genetic mutation implicated in KCNQ2 epileptic encephalopathy. They ... a second case involving an additional KCNQ2 genetic ... Alliance and Pairnomix entered into a collaboration to ...
(Date:7/20/2017)... NV (PRWEB) , ... July 20, 2017 , ... ... real solution to make clinical trial sites and study participants truly unified. TrialKit, ... regulatory compliant (FDA 21 CFR Part 11) research studies entirely on mobile devices. ...
(Date:7/18/2017)... ... July 18, 2017 , ... Sourcing custom glass or quartz ... and has the capabilities to properly execute your job can take many hours of ... is a sourcing portal designed to showcase the company’s capabilities and core custom categories, ...
Breaking Biology Technology:
(Date:3/28/2017)... India , March 28, 2017 ... IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software ... Vertical, and Region - Global Forecast to 2022", published ... Billion in 2016 and is projected to reach USD ... between 2017 and 2022. The base year considered for ...
(Date:3/24/2017)... DUBLIN , Mar 24, 2017 Research ... Vehicle Access System Market Analysis & Trends - Industry Forecast to ... ... poised to grow at a CAGR of around 15.1% over the ... This industry report analyzes the market estimates and forecasts for ...
(Date:3/22/2017)... 2017   Neurotechnology , a provider of ... announced the release of the SentiVeillance 6.0 ... facial recognition using up to 10 surveillance, security ... The new version uses deep neural-network-based facial detection ... utilizes a Graphing Processing Unit (GPU) for enhanced ...
Breaking Biology News(10 mins):